摘要
目的 研究2种头孢拉定颗粒剂的相对生物利用度,评价其生物等效性。方法 18名健康受试者随机交叉单剂量口服2种颗粒剂0.5g后,经不同时间点取血,血浆样品采用新建立的HPLC法测定,研究两者的生物利用度。结果 头孢拉定颗粒A和B的Cmax分别为(21.18±4.01)、(21.05±3.41)μg·mL^-1;tmax分别为(0.54±0.13)、(0.54±0.10)h;AUC0~5分别为(24.84±4.71)、(24.89±4.19)μg·h·mL^-1;AUC0~∞分别为(25,40±4.86)、(25.63±4.37)μg·h·mL^-1;t1′2别为(0.72±0.21)、(0.76±0.56)h。方差分析结果表明2种颗粒剂的参数之间没有显著性差异,头孢拉定颗粒A的相对生物利用度为(99.8%±11.4%)。结论 2种头孢拉定颗粒剂具有生物等效性。
Objective To determine the relative bioavailability of 2 cefradine pellets and to evaluate the bioequivalence. Methods According to the crossover design, each volunteer was given a single oral dose of 0. 5 g cefradine pellets, and then the plasma was obtained and determined by the newly-developed HPLC method. Results The pharmacokinetic parameters of the cefradine pellets A and B in the plasma were as follows: Cmax was (21.18 ± 4.01), (21.05 ± 3.41) μg ·mL^-1 ; tmax was (0.54 ± 0.13), (0.54 ± 0.10) h; AUC0~5 was (24.84 ±4.71), (24. 89± 4. 19) μg· h· mL^-1; AUC0~5 was (25.40±4.86), (25.63 ± 4.37) μg·h ·mL^-1 ; t1/2 was (0.72 ± O. 21), (0. 76 ± 0. 56) h. The relative bioavailability of cefra- dine pellet A was (99.8±%11.40%). Conclusion The two one-sided t tests showed that the 2 cefradine pellets were bioequivalent.
出处
《中南药学》
CAS
2008年第1期67-69,共3页
Central South Pharmacy
关键词
头孢拉定颗粒剂
生物等效性
HPLC
cefradine pellets bioequivalence High Performance Liquid Chromatography